Vantictumab
Overview
Vantictumab is a fully human monoclonal antibody that targets multiple Frizzled receptors involved in the Wnt signaling pathway. By blocking Frizzled receptors 1, 2, 5, 7, and 8, it inhibits Wnt-driven tumor growth and is designed to target cancer stem cells.
Mechanism of Action
The therapeutic rationale is based on dysregulated Wnt signaling in various solid tumors, particularly breast and pancreatic cancers. Inhibition of this pathway may reduce tumor recurrence and metastatic potential.
Research Summary & Key Findings
Phase I trials in solid tumors demonstrated dose-limiting bone toxicity including fractures, which restricted further development. A phase Ib study in metastatic pancreatic cancer combined with chemotherapy was terminated early due to safety concerns (2016). Despite promising preclinical activity against cancer stem cells, clinical development has been halted.
Clinical Status
Vantictumab is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
References
Primary literature
- PubMed — "Vantictumab"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Vantictumab"
Registered interventional and observational studies, including status and phase.
- PubChem — "Vantictumab"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Oncology
Carfilzomib (Kyprolis)
FDA ApprovedA tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds the chymotrypsin-like (beta5) subunit of the 20S...
View detailsBortezomib (Velcade)
FDA ApprovedA modified dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Bortez...
View detailsLutetium-177 dotatate (Lutathera)
FDA ApprovedA radiolabeled somatostatin analog consisting of the peptide DOTA-Tyr3-octreotate chelated to the beta-emitting radioiso...
View detailsLeuprolide (Lupron) - Oncology
FDA ApprovedA GnRH agonist used in oncology for androgen deprivation therapy (ADT) in prostate cancer and hormone suppression in pre...
View detailsStart Your Consultation
Get an AI-proposed Vantictumab protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Vantictumab.
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.